Placeholder

The Rise of Biosimilars

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 2991.

Product Description

The biotechnology market in the United States is about to be altered significantly. In July, Sandoz announced it was the first company to file an application under the biosimilars pathway created by the Biologics Price Competition and Innovation Act. This act, which was part of the Affordable Care Act that was signed into law by President Barack Obama on March 23, 2010, created the regulatory pathway for an abbreviated process for…

Sidebars:
Defining Biosimilar
Physician Perspectives on Biosimilars
Approved Biosimilars in Europe
Biosimilars and the FDA

 

FEEDBACK